With the city hall scandals in Toronto and Montreal, Canada is looking more like its southern neighbor than ever
United and Delta will measure the passenger's financial value to the airline instead of the miles she's logged
The good news? People tend to moderate the extremity of their views on complicated issues after they've tried to explain how they actually work
A debate between Ribbit Capital's Micky Malka and Tangent Capital's Jim Rickards changed audience members' minds about the virtual currency
A new report finds debt relief firms charge for help debtors can get for free
The agency pitched to potential partners its plan to snare earthbound asteroids with spacecraft
A classic game comes just in time
Business students may think their choice of major makes them career-saavy, but PayScale says they're the most underemployed college graduates of all
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."